GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
The $17 Billion Race: Why New Treatments for Alzheimer’s Disease Are Changing the Game
The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action. Experts are encouraged to see a broader range of therapeutic options emerging in the pipeline for patients.
The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early
For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors
Why We Can't Sleep in Early Alzheimer's: The New Science of Brain Inflammation
For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain.
Bridging the Gap: How Glassbury AI is Making Medical Research Work for Everyone
At Glassbury AI, we believe health justice starts with inclusion. We are using modern technology to fix this recruitment crisis by building trust and making the process easy to understand for every family.
Alzheimer’s & the GRK2 Enzyme: A Sleeping Key to Brain Energy
Discover how ETH Zurich researchers uncovered GRK2 enzyme aggregates as a novel Alzheimer's target, offering new hope for energy-restoring therapies.
AI Brain Map Predicts Early-Onset Alzheimer's Progression
When most people picture Alzheimer's disease, they imagine an individual in their late 70s or 80s gradually experiencing memory loss. However, Early-Onset Alzheimer's Disease (EOAD) paints a starkly different, often heartbreaking picture. Striking individuals under the age of 65—frequently in their 40s or 50s—EOAD attacks people who are at the very peak of their personal and professional lives.
Unlocking Clinical Equity: How Glassbury AI Meets FDA Diversity Action Plan Mandates in Alzheimer’s Research
Explore how Glassbury AI uses Google Cloud, MedGemma, and Vertex AI Explainable AI to guarantee FDA Diversity Action Plan compliance and accelerate Alzheimer's clinical trial matching.
A Legacy of Mistrust: Understanding and Addressing Vaccine Hesitancy Among People of Color
The recent COVID-19 pandemic has laid bare a stark reality: people of color (POC) are disproportionately hesitant to engage with medical and governmental institutions, particularly regarding vaccinations. This hesitancy, often labeled as "vaccine hesitancy," is not simply a matter of ignorance or fear. It is rooted in a deeply ingrained distrust that stems from a long history of systemic racism and medical discrimination.
The Hurdles in the Path to Cures: The Unique Challenges of Rare Disease Research
Rare diseases, despite affecting millions of people worldwide, often exist in a shadow cast by more prevalent illnesses. Their rarity presents a unique set of challenges for researchers striving to develop effective treatments and cures. From limited funding to small patient populations, the path to conquering rare diseases is fraught with obstacles.
The Role of Government in Fostering a Thriving Entrepreneurial Environment for Drug Research and Development
The United States government plays a pivotal role in shaping the landscape for drug research and development (R&D), fostering an environment where entrepreneurial endeavors can flourish. This blog post delves into the multifaceted ways in which the government contributes to this ecosystem, drawing insights from authoritative sources and expert opinions.
Caregivers and Mental Health: The Unsung Heroes Need Support Too
Caregiving is an act of profound love and dedication, but it can also be a challenging journey filled with emotional, physical, and mental strain.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.
Alzheimer’s Breakthrough: Why Tau-Targeting Therapies Are Changing the Game
Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.
Stop Treating Patients Like QR Codes: The AI-Powered Guide to Truly Diverse Clinical Trials
If your clinical trial recruitment strategy still relies on cold-calling lists of "eligible" patients scraped from five-year-old EHR data, you aren’t just behind the times—you’re actively sabotaging your own FDA compliance.